The present invention relates to cells with altered cell cycle control. In particular, the present invention provides cells with altered cell cycle control and uses of such cells to identify metabolically active agents.

In one aspect, the present disclosure provides a method for identifying treatment targets relating to tumors. In another aspect, the present disclosure provides a method for identifying biomarkers and molecular features of normal and cancer cells.

The disclosure provides methods for enriching for pancreatic endocrine progenitor cells, such as human pancreatic endocrine progenitor cells, including alpha cell progenitors, beta cell progenitors, delta cell progenitors, PP cell progenitors and epsilon cell progenitors. The disclosure provides mammalian, such as human, Fev.sup.+ pancreatic endocrine progenitor cells, including Fev.sup.+ alpha cell progenitors, Fev.sup.+ beta cell progenitors, Fev.sup.+ delta cell progenitors, Fev.sup.+ PP cell progenitors, and Fev.sup.+ epsilon cell progenitors. The disclosure further provides methods for producing or inducing such cells, including in vitro differentiation methods, and the cells so produced.

The present disclosure provides materials and methods for the delivery of therapeutic nucleic cells (and imaging agents) to tissues.

This document provides materials and methods for making and using functional (e.g., vascularized) organ models (e.g., pancreas models). For example, functional pancreas models including an ECM containing a plurality (e.g., two or more) of pancreatic islets, and a vascular network are provided.

Microfluidic systems including a housing configured to receive a cartridge, the cartridge including a plurality of wells for receiving one or more biological cells are described herein. The microfluidic systems include a structure with channels for introducing a medium into the housing and through channels the cartridge. Microfluidic systems including a housing configured to receive a cartridge, the housing including channels for loading one or more biological cells within wells of the cartridge are described herein. Three-dimensional scaffolds, devices, and systems comprising such scaffolds that mimic the in vivo structure, physical properties, and protein composition of extracellular matrix surrounding pancreatic islet cells and adipocytes, and the use of such compositions, devices and systems for, e.g., in vitro drug screening and/or toxicity assays, disease modeling, and therapeutic applications are also described herein.

In one aspect, the present disclosure provides a method for identifying treatment targets relating to tumors. In another aspect, the present disclosure provides a method for identifying biomarkers and molecular features of normal and cancer cells.

Disclosed herein are methods for generating SC-β cells, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

Provided herein are methods of differentiating stem cells via modulating miR-124, and the differentiated cells thereby. Also provided herein are methods for the treatment of diseases using the differentiated cells.

The present invention relates to the fields of immunology and diabetes. More specifically, the present invention provides methods and compositions directed to the use of antibodies to quantify cellular pancreatic zinc transporter 8. In certain embodiment, the present invention provides methods and compositions directed to the use of antibodies to screen for modulators of the pancreatic zinc transporter, ZnT8. In one embodiment, a method comprises the steps of (a) permeabilizing human beta cells present in a substrate; (b) contacting the cells with a test agent; and (c) measuring the amount of zinc transporter 8 (ZnT8) using at least one anti-ZnT8 antibody or antigen-binding fragment thereof.